2020
Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States
Menzies NA, Bellerose M, Testa C, Swartwood N, Malyuta Y, Cohen T, Marks SM, Hill AN, Date AA, Maloney SA, Bowden SE, Grills AW, Salomon JA. Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. American Journal Of Respiratory And Critical Care Medicine 2020, 202: 1567-1575. PMID: 32645277, PMCID: PMC7706168, DOI: 10.1164/rccm.202003-0526oc.Peer-Reviewed Original ResearchConceptsGlobal TB controlTB incidence trendsEnd TB StrategyTB controlTB casesIncidence trendsEconomic burdenWorld Health Organization's End TB StrategyTB incidence rateGlobal tuberculosis controlHigh-burden countriesTotal economic burdenMajor health benefitsBase case scenarioBirth countryTB incidenceTB epidemiologyTuberculosis controlTB StrategyIncidence rateHealthcare costsIncidence reductionInfection riskTuberculosisSubstantial health
2016
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health 2016, 4: e816-e826. PMID: 27720689, PMCID: PMC5527122, DOI: 10.1016/s2214-109x(16)30265-0.Peer-Reviewed Original ResearchMeSH KeywordsChinaCost-Benefit AnalysisDelivery of Health CareForecastingGoalsHealth Care CostsHealth ExpendituresHealth PolicyHealth ResourcesHealth Services AccessibilityHealth Services Needs and DemandHumansIndiaModels, TheoreticalPatient Acceptance of Health CareQuality-Adjusted Life YearsSouth AfricaTuberculosisConceptsPatient-incurred costsTuberculosis servicesConventional cost-effectiveness thresholdsHigh-burden countriesEnd TB StrategySubstantial health gainsNet cost savingsResource implicationsCost-effectiveness thresholdMost intervention approachesTB StrategyTuberculosis incidenceMost interventionsSocietal perspectiveHealth gainsIntervention mixMelinda Gates FoundationSubstantial healthHealth effectsCurrent practiceExpansion of accessIntervention approachesEmpirical cost dataCost dataInterventionFeasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models
Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin HH, Wu CY, Mandal S, Pandey S, Suen SC, Bendavid E, Azman AS, Dowdy DW, Bacaër N, Rhines AS, Feldman MW, Handel A, Whalen CC, Chang ST, Wagner BG, Eckhoff PA, Trauer JM, Denholm JT, McBryde ES, Cohen T, Salomon JA, Pretorius C, Lalli M, Eaton JW, Boccia D, Hosseini M, Gomez GB, Sahu S, Daniels C, Ditiu L, Chin DP, Wang L, Chadha VK, Rade K, Dewan P, Hippner P, Charalambous S, Grant AD, Churchyard G, Pillay Y, Mametja LD, Kimerling ME, Vassall A, White RG. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health 2016, 4: e806-e815. PMID: 27720688, PMCID: PMC6375908, DOI: 10.1016/s2214-109x(16)30199-1.Peer-Reviewed Original ResearchConceptsEnd TB Strategy targetsPreventive therapyTuberculosis incidenceContinuous isoniazid preventive therapyGlobal tuberculosis targetsIsoniazid preventive therapySymptoms of tuberculosisActive case findingNational Tuberculosis ProgrammeEnd TB StrategyHigh-burden countriesAntiretroviral therapyLatent tuberculosisStrategy targetsTuberculosis burdenTuberculosis careTuberculosis ProgrammeTB StrategyTuberculosis transmissionHealth centersAdditional interventionsTuberculosis interventionsCase findingTuberculosis epidemiologyEpidemiological impact
2012
Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country
Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A, Zignol M, Dadu A, Dara M, Cohen T. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. European Respiratory Journal 2012, 42: 1291-1301. PMID: 23100496, PMCID: PMC3800490, DOI: 10.1183/09031936.00111812.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB riskMDR-TB risk factorsNational TB surveillance dataMDR-TB incidenceTB surveillance dataMDR-TB casesHigh-burden countriesMDR-TB burdenDistribution of casesTB casesTuberculosis casesRisk of resistanceRisk factorsGreater riskSubstantial geographical variationSurveillance dataAppropriate targetingTesting coverageRiskTuberculosisBurdenHigh percentageLocal mechanismsPatients
2011
Tuberculosis Among Participants in an Academic Global Health Medical Exchange Program
Gardner A, Cohen T, Carter EJ. Tuberculosis Among Participants in an Academic Global Health Medical Exchange Program. Journal Of General Internal Medicine 2011, 26: 841-845. PMID: 21359579, PMCID: PMC3138970, DOI: 10.1007/s11606-011-1669-x.Peer-Reviewed Original ResearchConceptsDirect medical careTST conversionTB infectionBurden countriesMedical careLow tuberculosis (TB) burden countriesTuberculin skin test conversionSkin test conversionTB endemic areasPre-travel preparationTuberculosis burden countriesHigh-burden countriesLength of stayTB educationTB preventionTB screeningTB testingTest conversionPercentage reportingDevelopment of guidelinesInadequate preDemographic characteristicsLonger durationExchange programsCare